Selective inhibitors interfering with fibroblast growth factor receptor and FRS2 interaction for the prevention and treatment of cancer and other diseases

A method for selectively interfering with the interaction between the fibroblast growth factor receptor (FGFR) and the fibroblast growth factor receptor substrate 2 (FRS2) complex in a subject comprising:

• administering to the subject a therapeutically effective amount of a compound of general formula I:
• or a pharmaceutically acceptable salt thereof,
• wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 are the same or different and are independently selected from —NH2, —NO2, —CH3, —F, —Cl, —Br, —I, —CF3, —OCH3, —C2H5, —H, substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclic groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, and substituted or unsubstituted heterocyclyloxyalkyl groups;
• and
• X is CH or N.